Why the study?
Do toxic substances in the blood of patients with uremia due to ESRD induce conformational changes in ACE that alter the efficacy of ACE inhibitors?
Do toxic substances in the blood of patients with uremia due to ESRD induce conformational changes in ACE that alter the efficacy of ACE inhibitors?
A subpopulation of ESRD patients exhibits conformationally altered blood ACE that is less suppressible by ACE inhibitors, suggesting they may require higher doses for effective anti-hypertensive therapy.
No takes yet. Share an insight, caveat, or question.
May blunt ACE inhibitor efficacy in select ESRD patients; leaves open need for dose adjustment or outcome impact pending prospective data.
Petrov et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: